In last trading session, Neumora Therapeutics Inc (NASDAQ:NMRA) saw 1.54 million shares changing hands with its beta currently measuring 2.52. Company’s recent per share price level of $1.66 trading at -$0.07 or -4.05% at ring of the bell on the day assigns it a market valuation of $268.19M. That closing price of NMRA’s stock is at a discount of -1165.06% from its 52-week high price of $21.00 and is indicating a premium of 3.61% from its 52-week low price of $1.60.

For Neumora Therapeutics Inc (NMRA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.44. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.41 in the current quarter.

Neumora Therapeutics Inc (NASDAQ:NMRA) trade information

Upright in the red during last session for losing -4.05%, in the last five days NMRA remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $1.66 price level, adding 7.52% to its value on the day. Neumora Therapeutics Inc’s shares saw a change of -84.34% in year-to-date performance and have moved -0.60% in past 5-day. Neumora Therapeutics Inc (NASDAQ:NMRA) showed a performance of -19.02% in past 30-days.

Wall Street analysts have assigned a consensus price target of 4 to the stock, which implies a rise of 58.5% to its current value. Analysts have been projecting 4 as a low price target for the stock while placing it at a high target of 4. It follows that stock’s current price would drop -140.96% in reaching the projected high whereas dropping to the targeted low would mean a loss of -140.96% for stock’s current value.

In 2025, company’s earnings growth rate is likely to be around 56.61% while estimates for its earnings growth in next 5 years are of 24.06%.